BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
Biopharmaceutical company Ascentage Pharma Group International (6855.HK) received a listing approval notice from the China Securities Regulatory Commission (CSRC) on Monday, a necessary step before it can make an overseas…
Ascentage Pharma soars on deal with cancer drug competitor
The Chinese drug developer put a rocket booster under its share price after enlisting a Japanese rival as a new equity partner and unveiling plans for a U.S. listing Key…
FAST NEWS: Ascentage’s manufacturing center gets EU stamp of approval
The latest: Ascentage Pharma Group International (6855.HK) announced on Tuesday it recently received a zero-deficiency report following a Good Manufacturing Practice (GMP) compliance audit of its global manufacturing center by…
FAST NEWS: Hutchmed, Zai Lab, Ascentage Drugs Land on China Reimbursement List
The latest: Products from Hutchmed (China) Ltd. (HCM.US; 0013.HK), Zai Lab Ltd. (ZLAB.US; 9688.HK) and Ascentage Pharma Group (6855.HK) were among 111 new drugs selected for new inclusion in the…
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Cancer drug maker ended a tie-up to bring one of its drugs to North America last week, less than two months after its best-selling product was rejected by the FDA…
Recent Articles
RELATED ARTICLES
-
Ascentage Pharma soars on deal with cancer drug competitor
6855.HK
- IPO tea party set to resume with Guming’s regulatory nod from China?
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK
-
Yeahka braces investors for bad first half while trying to depict a rosy future
9923.HK
- Mao Geping’s Hong Kong IPO gets lift from regulatory nod
- WeRide drives into Uber partnership, as U.S. listing plan idles
